Showing 1601-1610 of 5771 results for "".
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in the Czech Republichttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-the-czech-republic/2481212/Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis, through its distribu
- Outlook Therapeutics Announces Acceptance of BLA by FDA for ONS-5010 as a Treatment for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-acceptance-of-biologics-license-application-by-fda-for-ons-5010-as-a-treatment-for-wet-amd/2481206/Outlook Therapeutics announced that the FDA has accepted for filing a Biologics License Application (BLA) for ONS-5010/Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (AMD). The FDA set
- Vyluma Announces Positive Results From Phase 3 CHAMP Study of NVK002 for Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-announces-positive-results-from-phase-3-champ-study-of-nvk002-for-treatment-of-myopia-progression-in-children/2481205/Vyluma announced topline results from its phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. Analysis of this multicenter, international study, performed after 3 years of treatment and follow up, demonstrates strong safety and efficacy for NVK002 as a potential treatment fo
- Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meetinghttps://modernod.com/news/tarsus-to-present-additional-saturn-2-pivotal-phase-3-trial-data-at-the-american-academy-of-optometry-2022-annual-meeting/2481189/Tarsus Pharmaceuticals announced that additional efficacy results from the Saturn-2 pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) in Demodex blepharitis patients will be presented at the upcoming American Academy of Optometry 2022 Annual Meeting in San D
- Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meetinghttps://modernod.com/news/ocuphire-announces-six-poster-presentations-on-nyxol-and-apx3330-at-the-american-academy-of-optometry-annual-meeting/2481187/Ocuphire Pharma announced acceptance and presentation of six posters featuring Nyxol and APX3330 at the
- Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol for the Treatment of Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-fda-acceptance-of-the-new-drug-application-for-cyclasol-for-the-treatment-of-dry-eye-disease/2481186/Novaliq announced that the FDA has accepted the new drug application (NDA) for CyclASol (cyclosporine ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED). The agency completed the filing revi
- Eyenovia Announces Positive Results From VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-results-from-vision-2-phase-3-study-of-microline-as-a-potential-on-demand-treatment-for-presbyopia/2481181/Eyenovia announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia. The VISION-2 study evaluated the safety and efficacy of Eyenovia’s 2% pilocarpine micro-array print (MAP) formulation versus placebo, all administered
- Olleyes Announces Partnership With Tobii to Incorporate Advanced Eye Tracking Features Into VisuALL ETS Modelhttps://modernod.com/news/olleyes-announces-partnership-with-tobii-to-incorporate-advanced-eye-tracking-features-into-visuall-ets-model/2481178/Olleyes announces a partnership with Tobii to incorporate advanced eye tracking features within the VisuALL Virtual Reality Platform (VRP) ETS package. Tobii technology will further enhance the capabilities of the Olleyes VisuALL ETS to deliver a variety of ophthalmic tests with superior acc
- Oculis SA and European Biotech Acquisition Corp Announce Agreement to Create Nasdaq-Listed Biopharmaceutical Companyhttps://modernod.com/news/oculis-sa-and-european-biotech-acquisition-corp-announce-agreement-to-create-nasdaq-listed-biopharmaceutical-company/2481177/Oculis SA and European Biotech Acquisition Corp (EBAC) announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named “Oculis Holding SA” and will work to accelerate the development of Oculis&rsqu
- Tarsus Announces Transition Plans for Board of Directorshttps://modernod.com/news/tarsus-announces-transition-plans-for-board-of-directors/2481168/Tarsus Pharmaceuticals announced several expected upcoming transitions to its Board of Directors by year-end. Tarsus Co-Founder and Chairman, Michael Ackermann, PhD, plans to transition off the Board of Directors. Upon Dr. Ackermann’s planned transition, Wendy Yarno, industry veteran and cu